Present
Bruce H. Thiers, MD, FAAD, President
Susan C. Taylor, MD, FAAD, Vice President
George J. Hruza, MD, MBA, FAAD, Immediate Past President
Marta J. Van Beek, MD, MPH, FAAD, Secretary-Treasurer
Daniel D. Bennett, MD, FAAD, Assistant Secretary-Treasurer
Kenneth J. Tomecki, MD, FAAD, President-Elect
Neal D. Bhatia, MD, FAAD, Vice President-Elect
Abby S. Van Voorhees, MD, FAAD
Amy McMichael, MD, FAAD
Andrew H. Weinstein, MD, MPH, FAAD
Cheryl M. Burgess, MD, FAAD
Diane S. Berson, MD, FAAD
James Q. Del Rosso, DO, FAAD
Murad Alam, MD, FAAD
Naomi Lawrence, MD, FAAD
Patricia K. Farris, MD, FAAD
Robert S. Kirsner, MD, PhD, FAAD
Robert A. Weiss, MD, FAAD
Seemal R. Desai, MD, FAAD
Valerie D. Callender, MD, FAAD
Adelaide Hebert, MD, FAAD
Alexander Miller, MD, FAAD
Lawrence Green, MD, FAAD
Cyndi Yag-Howard, MD, FAAD

Incoming Board Members
Mark D. Kaufmann, MD, FAAD, President-elect
Linda F. Stein Gold, MD, FAAD, Vice President-elect
April W. Armstrong, MD, MPH, FAAD
Lindy P. Fox, MD, FAAD
Maria K. Hordinsky, MD, FAAD
Jennifer Lucas, MD, FAAD

Staff
Elizabeth K. Usher, MBA, Executive Director and CEO
Robert M. Portman, JD, General Counsel
Barbara Greenan, Chief Advocacy and Policy Officer
Cindy Kuhn, Chief Member Engagement Officer
Damon Marquis, MA, MS, FACEHP, Chief Learning Officer
Krista D. Kauper, JD, Chief Officer of Strategic Alliances and Planning
Matthew Fitzgerald, DrPH, Chief Science & Quality Officer
Steven Debnar, MBA, Chief Financial Officer
Melanie Tolley Hall, Chief Communications and Marketing Officer
Sarah Tancredi, MBA, PHR, Chief Operations Officer
Erik Horn, Senior Director, Information Technology
Tim Moses, CMP, Senior Director, Meetings and Conventions
Beth Laws, Director, Advocacy and Policy Operations
Cyndi Del Boccio, Director, Executive Office
CALL TO ORDER
Bruce H. Thiers, MD, FAAD, President and presiding, called the meeting of the Board of Directors of the American Academy of Dermatology and Association to order at 12:19 pm (CST) on Saturday, November 7, 2020.

QUORUM
Marta J. Van Beek, MD, MPH, FAAD, Secretary-Treasurer declared that a quorum was present for the transaction of business.

ORDER OF BUSINESS/INTRODUCTORY MATTERS
Antitrust Compliance Policy, Fiduciary Obligations, and Note Taking
Dr. Van Beek referred the Board members to the background materials regarding the AAD/A Antitrust Compliance Policy, note taking during meetings, and separate order of business, and reminded them about the importance of following their fiduciary obligations, including maintaining confidentiality and declaring conflicts of interest.

Disclosure of Outside Interests and Management of Conflicts of Interest, Code of Conduct, Confidentiality Agreement and Copyright Assignment of Work Product Policies
The Board members’ disclosures of outside interests and code of conduct were posted to BoardEffect. Dr. Van Beek asked Board members to declare any other actual or potential conflicts of interest with respect to specific agenda items for this meeting. None were declared. She also reminded them to declare any potential conflicts of interest when an agenda item was being discussed prior to speaking in favor of or against the motion on the floor.

Separate Order of Business
Dr. Van Beek reminded the Board members that they would be following the American Institute of Parliamentarians Standard Code of Parliamentary Procedure (formerly Sturgis Code of Parliamentary Procedure), and that it is essential that the AADA follow the order of business and observe corporate formalities necessary to ensure the separateness of the two organizations.

AADA OFFICER AND DIRECTORS REPORTS
Dr. Thiers reminded the Board that his report, the Secretary-Treasurer’s report, the Executive Director’s report and the International, Young Physician’s and Residents/Fellows Board Observer reports were presented during the Academy Board meeting.

SkinPAC Announcement
George J. Hruza, MD, FAAD, Immediate Past President, presented a status report on SkinPAC’s performance during this election cycle. He noted that SkinPAC received $1.6 million in member contributions in 2019-20. He noted that 94% of candidates that SkinPAC supported in this cycle were successful. He said that SkinPAC created an honor roll for members who contribute $2500 or more. He thanked the Board members for their contributions to SkinPAC.
AADA STRATEGIC ISSUES

Rapid Response Team on Scope of Practice/Truth-in-Advertising (“Triage Team”)

Dr. Van Beek referred the Board to page 2 of the Board background materials and presented the Rapid Response (Triage) Team on Scope of Practice/Truth-in-Advertising's report. She discussed the charge of Triage Team, the process for processing member complaints, and the types of cases being handled. She also noted that the AADA has refreshed the website graphics for “Choose a Board-Certified Dermatologist, is taking steps to promote the use of the FAAD designation, and is engaged in a member education campaign, including through a Dermatology World article, on what the AADA can and cannot do to respond to violations of scope of practice and truth in advertising laws by non-dermatologist physicians and non-physicians, especially with respect to antitrust issues. Dr. Van Beek also discussed specific scope of practice threats, including the 2020 revisions to the Advanced Practice Registered Nurse (APRN) Compact, which allows advanced practice registered nurses to hold one multistate license with a privilege to practice in other compact states. She also discussed model legislation that would allow several different kinds of Registered Nurses to practice and prescribe independently. She next discussed the impact of COVID-19 waivers of supervision requirements and executive orders that provide pay parity between physicians and non-physicians under Medicare Advantage plans.

A motion was made and duly seconded to approve the Rapid Response Team on Scope of Practice/Truth-in-Advertising (“Triage Team”) reports of June 8, August 3, and October 1, 2020 for information only.

ACTION: Approved

Heard from the Field

Dr. Thiers invited Board members to raise issues of concern that they were hearing out in the field. During this time, Mark D. Kaufmann, MD, FAAD, Incoming President-Elect, presented a report on some expected announcements from the CMS regarding use of 10-day global codes which are all from the same destruction codes.

Seemal Desai, MD, FAAD also provided an update on compounding issues. He first discussed the formal release of the final Food and Drug Administration guidance on unsanitary conditions for compounding facilities that states that the agency does not intend to personally enforce or take action against individual physicians performing compounding in their office for particular patients. He then noted that the AADA is continuing to work with the U.S. Pharmacopeia in its development of a monograph for buffered lidocaine.

The Board recessed so that it could take up AAD business at 1:11 pm (CST).

The Board reconvened the AADA Board meeting at 4:57 pm (CST).

Bylaws Committee

AADA Bylaws

Dr. Thiers stated that the proposed amendments to the AAD Bylaws Articles V, IX, and XVI were presented during the AAD meeting.

A motion was made and duly seconded to take the same actions for the AADA bylaws, where applicable, as were taken for the AAD bylaws.

ACTION: Approved
AADA NEW BUSINESS

Advisory Board pages 3-6 of Board materials

AADA001 (S-20): AAD/A Summer 2020 – Overreaching Government Power in a Pandemic

Andrew H. Weinstein, MD, MPH, FAAD referred the Board to page 3 of the Board background materials and presented the following Advisory Board resolution for Board review and action:

RESOLVED, that the AADA, with the AMA if feasible, send letters to state Governors, state boards of healing arts, and state pharmacy boards, which includes the following points:

1. A physician’s primary responsibility is to the patient.
2. The patient and the physician have the right to determine appropriate treatment for the patient’s condition, including off label use, after the disclosure of potential risks and benefits.
3. Physicians make decisions based on available scientific evidence. Governmental advice and recommendations for treatment may be appropriate additional considerations.

A motion was made and duly seconded to refer this resolution to the State Policy Committee.

ACTION: Approved

AADA003 (S-20): Telemedicine

Dr. Weinstein next presented the following resolution for Board review and action.

RESOLVED, teledermatology is a useful method of evaluating dermatology patients, but the gold standard of patient evaluation remains an in-person visit with a dermatologist.

A motion was made and duly seconded to refer this resolution to the Council on Practice Management, specifically to the Teledermatology Task Force.

ACTION: Approved

Council on Government Affairs and Health Policy (GAHP)

Interstate Medical Licensure Compact (IMLC) pages 7-13

Seemal R. Desai, MD, FAAD referred the Board to pages 7-13 of the background materials and presented the report of the Council on Government Affairs and Health Policy (GAHP). Dr. Desai stated that, at the request of the AADA Board of Directors, the State Policy Committee reviewed and considered Advisory Board (AB) resolution AADA-05 (S-19), “Opposition to Encroachment of our Medical License.” He stated that the Council on GAHP had previously supported the IMLC because it provides an expedited pathway to licensure for qualified physicians who wish to practice in multiple states and facilitates teledermatology by AAD members. Dr. Desai stated that the ILMC was developed by the Federation of State Medical Boards and has been adopted into law in 29 states, to date. He discussed the pros and cons of the ILMC. He noted that the State Policy Committee unanimously recommended that the Board continue to support the ILMC. He said the Council on GAHP was divided but voted 7-6 for the same recommendation.

Dr. Weinstein presented the position of the Advisory Board in support of this resolution. Other Board members discussed the advantages and disadvantages of the ILMC.

A motion was made and duly seconded to approve the Council on GAHP recommendation that the AADA maintain its current position of support for the IMLC.

ACTION: Approved
A motion was made and duly seconded to approve the rest of the Council on Government Affairs and Health Policy report for information only.

**ACTION:** Approved

A motion was made and duly seconded to approve the updated Ad Hoc Task Force on COVID-19 report for information only, and that the Association takes the same actions as were taken by the Academy Board of Directors for all of the other applicable reports and actions.

**ACTION:** Approved

**ADJOURNMENT**

There being no further business, Dr. Thiers adjourned the AADA Board of Directors Meeting at 5:30 pm (CST).

Respectfully Submitted,

Marta J. Van Beek, MD, MPH, FAAD
Secretary-Treasurer